Paper Details
- Home
- Paper Details
Sensitive determination of deferasirox in blood of patients with thalassemia using dispersive liquid-liquid microextraction based on solidification of floating organic drop followed by HPLC-UV.
Author: AkramipourReza, FattahiNazir, GolpayeganiMohammad Reza
Original Abstract of the Article :
Deferasirox is an oral iron chelator that has been on the market since 2005 and has been a suitable replacement for injectable chelators. It is important to check the amount of this drug in the blood of patients due to side effects. In this study, a new dispersive liquid-liquid microextraction based...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.1016/j.jpba.2020.113735
データ提供:米国国立医学図書館(NLM)
A Sensitive Method for Deferasirox Detection: DLLME-SFO
Keeping [iron overload] in check is crucial for individuals with [thalassemia]. [Deferasirox], an oral iron chelator, plays a vital role in managing this condition. This study focuses on developing a highly sensitive and efficient method for [deferasirox determination] in the blood of patients with [thalassemia] using a technique called [dispersive liquid-liquid microextraction based on solidification of floating organic drop (DLLME-SFO)].
DLLME-SFO: A Simple and Powerful Tool
The researchers skillfully combined [DLLME-SFO] with [high-performance liquid chromatography-ultraviolet detection (HPLC-UV)] to achieve a highly sensitive and precise analytical method. They demonstrated its ability to detect [deferasirox] in blood samples down to [0.06 µg L-1], with excellent repeatability and reproducibility. The method is also remarkably simple and environmentally friendly, making it a valuable tool for routine monitoring of [deferasirox] levels in patients with [thalassemia].
Monitoring Deferasirox Levels for Optimal Treatment
Accurate monitoring of [deferasirox] levels is essential for ensuring [optimal treatment] and minimizing potential side effects. This new method provides a powerful tool for clinicians to effectively manage [iron overload] in patients with [thalassemia]. It's like having a trusty compass in the desert of iron overload – a guide to help navigate the treatment landscape and ensure the best possible outcome.
Dr. Camel's Conclusion
DLLME-SFO offers a sensitive and efficient method for deferasirox determination in patients with thalassemia. This advancement in analytical techniques will significantly improve iron overload management and patient outcomes. It's like discovering a new oasis in the desert of iron overload, providing a reliable source of information for clinicians and their patients.
Date :
- Date Completed 2021-06-17
- Date Revised 2021-06-17
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.